Approval · Notice of Compliance 2040 · 1999
ZOLOFT: Notice of Compliance 2040
Issued February 25, 1999
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2040
- Date
- February 25, 1999
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To provide for additional wording under clinical trials-obsessive compulsive disorder section of the pm to include pediatric and adolescent experience
- Therapeutic class
- Antidepressant, antipanic, antiobsessional agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZOLOFT | Not yet assigned | — |
Medicinal ingredients
- SERTRALINE HYDROCHLORIDE 25 MG per CAP
- SERTRALINE HYDROCHLORIDE 50 MG per CAP
- SERTRALINE HYDROCHLORIDE 100 MG per CAP